Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
NYSE COMPOSITE INDX
Gold
Crude Oil
BioTime, Inc.
(NY:
BTX
)
4.020
USD
UNCHANGED
Official Closing Price
/ Updated:
6:40 PM EDT, Jun 19, 2013
/
Add to My Watchlist
View:
Quote
Overview
Detailed Quote
Charting
Options
Historical Prices
News
All News
Press Releases
Related Stories
Blogs
Podcasts
Research
Quarterly Reports
Insider Filings
Other Filings
All news about BioTime, Inc.
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Biotime: The Trend Continues Up (BTIM)
October 21, 2010
from
Comtex SmarTrend® News Briefs
SmarTrend's Candlestick Scanner Detects Bearish Engulfing Pattern for Biotime (BTIM)
October 18, 2010
from
Comtex SmarTrend® News Briefs
BioTime’s CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010
October 14, 2010
from
Business Wire News Releases
BioTime’s CEO Michael West to Speak at GTCbio and Unveil 12 New Diverse Cell Lines to be Launched November 1, 2010
October 14, 2010
from
Business Wire News Releases
BioTime Announces Stock Ticker Symbol Change and Extension of Warrant Expiration Date
October 12, 2010
from
Business Wire News Releases
BioTime Announces Stock Ticker Symbol Change and Extension of Warrant Expiration Date
October 12, 2010
from
Business Wire News Releases
BioTime (BTIM) and Hadasit Bio-Holdings annouce Cell Cure and Teva Enter OpRegen Development and Commercialization Agreement
October 11, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6024677 for the full story.
Read More
from
StreetInsider.com News Articles
Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.
October 10, 2010
from
Business Wire News Releases
Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd.
October 10, 2010
from
Business Wire News Releases
Cell Cure Neurosciences’ Shareholders Will Invest $7.1 M in the Company’s Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases
October 10, 2010
from
Business Wire News Releases
Cell Cure Neurosciences’ Shareholders Will Invest $7.1 M in the Company’s Development of Innovative Stem Cell Treatments for Neural and Retinal Diseases
October 10, 2010
from
Business Wire News Releases
BioTime CEO Dr. Michael West and CMO Dr. David Jin to Present Keynote Addresses at The Sixth Chinese Congress in Regenerative Medicine and Stem Cell Therapy in Suzhou, P.R. China
September 16, 2010
from
Business Wire News Releases
BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2010
September 13, 2010
from
Business Wire News Releases
BioTime Announces Executive Management Changes
September 08, 2010
from
Business Wire News Releases
BioTime to Launch Seven New Embryonic Progenitor Cell Lines on September 1, 2010
August 26, 2010
from
Business Wire News Releases
BioTime Raises $9.2 Million in Warrant Discount Offer
August 19, 2010
from
Business Wire News Releases
BioTime, Inc. (BTIM) Posts Q2 Loss of $0.06, Wider Y/Y
August 16, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5902040 for the full story.
Read More
from
StreetInsider.com News Articles
BioTime Announces Second Quarter 2010 Financial Results and Recent Corporate Developments
August 16, 2010
from
Business Wire News Releases
Healthcare Bill Signing Flashback: Biotime Currently 22.6% Below its March 23rd 'Healthcare Bill Signing' Low of $6.47 (BTIM)
July 22, 2010
from
Comtex SmarTrend® News Briefs
BioTime Announces Addition of New Stem Cell Lines to Its Product Portfolio
July 21, 2010
from
Business Wire News Releases
BioTime, Inc. Provides Financial Information about Its Acquisition of ES Cell International Pte Ltd.
July 19, 2010
from
Business Wire News Releases
SmarTrend Watching for Rebound in Shares of Biotime After 4.67% Loss (BTIM)
July 16, 2010
from
Comtex SmarTrend® News Briefs
BioTime CEO Dr. Michael West to Present at the Agora Financial Investment Symposium 2010
July 09, 2010
from
Business Wire News Releases
BioTime Announces Passing of Board Director Dr. Robert N. Butler
July 06, 2010
from
Business Wire News Releases
BioTime (BTIM) Files 1.38M Common, 300K Warrant Shelf for Selling Shareholders
June 28, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5764033 for the full story.
Read More
from
StreetInsider.com News Articles
BioTime (BTIM) Commences Discount Warrant Offer
June 18, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5742401 for the full story.
Read More
from
StreetInsider.com News Articles
BioTime Commences Warrant Discount Offer
June 18, 2010
from
Business Wire News Releases
BioTime Announces Results of Vote at Annual Shareholders Meeting
June 14, 2010
from
Business Wire News Releases
BioTime (BTIM) Added to Russell 3000 Index and Russell Global Index
June 14, 2010
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=5725252 for the full story.
Read More
from
StreetInsider.com News Articles
BioTime Set to Join Russell 3000 Index
June 13, 2010
from
Business Wire News Releases
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Market XML and JSON Data API
provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays.
Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Press Release Service
provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates
Bots go here